FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

wasiiiigtoii,	D.C. 20349	

10	OMB APPROVAL											

3235-0287 Estimated average burden 0.5 hours per response:

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Sec	tion 30(n) (	or tne	investn	ient C	ompany A	CT OT	1940						
1. Name and Address of Reporting Person* WILSON TROY EDWARD				2. Issuer Name <b>and</b> Ticker or Trading Symbol  Kura Oncology, Inc. [KURA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
WILSC	<u>M IKU I</u>	EDWARD		-			000			-				X Directo	r		10% Ov	ner
(Last)	(F	irst)	(Middle)	3.	Date	of Earliest	Trans	saction (	Month	ı/Day/Yea	·)			X Officer below)	(give title		Other (s below)	pecify
KURA ONCOLOGY, INC.					01/29/2016								President and CEO					
			CLUMP 40E															
11119 N.	TORREY	PINES ROAD,	SUITE 125	-														
				—   4.	If Ame	endment, [	Date o	of Origin	al File	d (Month/	Day/\	rear)	6. Ir	ndividual or J	oint/Group	Filing	(Check App	licable
(Street)		•	0000											,	iled by One	Repo	rting Persor	ı
LA JOLI	LA C	A	92037											_	,		One Repor	
														Person		C triair	One repor	ıg
(City)	(S	tate)	(Zip)															
		To	ble I - Non-D				- A -		1 D:			0 11 Do		O				
		Id	DIE I - NOII-D	erivati	ve S	ecurities	SAC	quire	וט ,ג	sposec	01,	UI DE	nencian	y Owned				
Date				action 2A. Deemed Execution Dat if any (Month/Day/Year)		Date	e, Transaction Dispose Code (Instr.			ities Acquired (A) or d Of (D) (Instr. 3, 4 ar		5. Amour Securitie Beneficia Owned F	Forr	Form (D) or	m: Direct or Indirect	7. Nature of Indirect Beneficial Ownership		
					,		-		+		(4) 0	.	Reported Transact		'``		(Instr. 4)	
								e V	Amou	nt	(A) o (D)	Price		(Instr. 3 and 4)				
			Table II - De	rivativo	2 500	uritios	Λοα	uirod	Dic	nocod (	of o	r Don	oficially	Ownod			<u> </u>	
						ls, warr								Owneu				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	Execution Date, if any	4. Transa Code (		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			Of U D	7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivativ Securiti	ve es ally ig	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercis	able	Expiratio Date		itle	Amount or Number of Shares		(Instr. 4)			
Option to purchase common	\$4.8	01/29/2016		A		120,000		(1)		01/28/202	.6 C	Common stock	120,000	\$0.00	120,0	00	D	

#### **Explanation of Responses:**

1. This option vests in 48 equal monthly installments commencing on the grant date.

## Remarks:

Annette North, Attorney-in-fact 02/02/2016 for Troy Wilson

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.